Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical trials and preclinical pharmacology with no systematic review methodology.
PubMed 19629408 · doi:10.1007/s12325-009-0045-2
What was done
This narrative review synthesized pharmacology, preclinical mechanisms, and clinical trial evidence (including GISSI-Prevenzione, GISSI-HF, DINAMIT, and IRIS) evaluating prescription omega-3-acid ethyl esters (Omacor; 840 mg EPA+DHA per capsule, 38% DHA) for post-myocardial infarction secondary prevention, heart failure, arrhythmia modulation, and hypertriglyceridemia management.
What was found
The abstract reports no numerical effect sizes, odds ratios, or confidence intervals. It states qualitatively that prescription omega-3 ethyl esters reduced mortality and arrhythmic death in GISSI-Prevenzione, and lowered severe arrhythmic events and mortality in GISSI-HF. Preclinical rat models showed low-dose DHA (but not EPA) inhibited ischemia-induced arrhythmias. Doses of 3–4 g daily improved hypertriglyceridemia and related lipid markers.
Why it matters
It highlights clinical trial evidence distinguishing standardized prescription omega-3-acid ethyl esters from unregulated over-the-counter fish oils in post-MI and heart failure regimens.
Limits
The paper is an unsystematic narrative review rather than a primary trial or meta-analysis. The abstract provides no precise effect sizes, confidence intervals, or safety event rates, and relies partly on rodent mechanistic data.
Cited by
- supports The VITAL trial administered 840 milligrams per day of omega-3, which equals one capsule of Lovaza.